Enrolling By InvitationNCT06924697
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
Medication studyAges 18–75ChinaAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- ShanghaiSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: June 21, 2025
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 46
- Sponsor
- Shanghai East Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Locations
- China
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT06924697
- Official title
Show the full official title
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients: Study Protocol of a Randomized, Parallel -Controlled Clinical Trial
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Shanghai
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Shanghai East Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Application of GLP-1RAs drugs and DPP-4i group.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
